Journal Scans
Chronic Myeloid Leukemia (CML) With P190BCR-ABL: Analysis of Characteristics, Outcomes, and Prognostic Significance
CML With P190BCR-ABL Shows Poor Response to TKI Therapy
D Verma, HM Kantarjian, D Jones, R Luthra, G Borthakur, S Verstovsek, MB Rios, J Cortes
20090821
2009 Sept 21
Blood
Chronic Myeloid Leukemia (CML) With P190BCR-ABL: Analysis of Characteristics, Outcomes, and Prognostic Significance
Blood. 2009 Sept 21;114(11):2232-2235, D Verma, HM Kantarjian, D Jones, R Luthra, G Borthakur, S Verstovsek, MB Rios, J Cortes
TAKE-HOME MESSAGE
Abstract
Abstract
The most common BCR-ABL transcripts in chronic myeloid leukemia (CML) are e13a2(b2a2) and e14a2(b3a2). Other transcripts such as e1a2 are rare and their outcome with tyrosine kinase inhibitors (TKI) therapy is undefined. We analyzed 1292 CML patients and identified 14 with only e1a2 transcripts, 9 in chronic phase (CP), 1 in accelerated phase (AP), and 4 in blast phase (BP). Of the CP, 4 achieved complete hematologic response (CHR); 2, complete cytogenetic response (CCyR); 2, partial cytogenetic...
